-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111

Benzinga·08/17/2026 13:22:39
Listen to the news
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $105 to $111.